→
Pfizer Inc (PFE) is currently trading at $25.82, reflecting a modest increase of 0.12% today. The company has a market cap of $146.99B, but its year-over-year EPS growth is down by 5.26%, indicating potential challenges in profitability. Despite a solid dividend yield of 6.67% and beating earnings estimates consistently over the past four quarters, the overall revenue growth is only 1.36% YoY, suggesting stagnation in demand. With a P/E ratio of 19.68, PFE appears fairly valued against its earnings performance, warranting a neutral stance.
Maintain a neutral position on Pfizer Inc (PFE) as it navigates mixed growth and valuation indicators.
Pfizer's strong dividend yield of 6.67% is attractive for income-focused investors, providing a steady return. Furthermore, the company has consistently beaten earnings estimates, with Q1 2026 actual EPS at $0.75 versus expectations of $0.7243, showcasing resilience in challenging market conditions.
The company's year-over-year EPS decline of 5.26% suggests deteriorating profitability, while revenue growth of only 1.36% indicates stagnation in sales. Additionally, with the stock trading at a P/E of 19.68, the valuation may be stretched given the current growth trajectory.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Helm's AI rates PFE as Neutral. Maintain a neutral position on Pfizer Inc (PFE) as it navigates mixed growth and valuation indicators.
The company's year-over-year EPS decline of 5.26% suggests deteriorating profitability, while revenue growth of only 1.36% indicates stagnation in sales. Additionally, with the stock trading at a P/E of 19.68, the valuation may be stretched given the current growth trajectory.
Pfizer's strong dividend yield of 6.67% is attractive for income-focused investors, providing a steady return. Furthermore, the company has consistently beaten earnings estimates, with Q1 2026 actual EPS at $0.75 versus expectations of $0.7243, showcasing resilience in challenging market conditions.
Pfizer Inc (PFE) is currently trading at $25.82, reflecting a modest increase of 0.12% today. The company has a market cap of $146.99B, but its year-over-year EPS growth is down by 5.26%, indicating potential challenges in profitability. Despite a solid dividend yield of 6.67% and beating earnings estimates consistently over the past four quarters, the overall revenue growth is only 1.36% YoY, suggesting stagnation in demand. With a P/E ratio of 19.68, PFE appears fairly valued against its earnings performance, warranting a neutral stance.
Pfizer Inc (PFE) is currently trading at $25.82, reflecting a modest increase of 0.12% today. The company has a market cap of $146.99B, but its year-over-year EPS growth is down by 5.26%, indicating potential challenges in profitability. Despite a solid dividend yield of 6.67% and beating earnings estimates consistently over the past four quarters, the overall revenue growth is only 1.36% YoY, suggesting stagnation in demand. With a P/E ratio of 19.68, PFE appears fairly valued against its earnings performance, warranting a neutral stance. Our overall verdict is Neutral.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for PFE at helmterminal.dev/analyze/PFE, updated continuously during US market hours. No signup required.